Forging ahead with its lupus drug, Prestara, Genelabs Technologies Inc. has decided to conduct another Phase III trial, and likely will look for a development partner to help offset costs. (BioWorld Today)

Expecting to triple the revenues from its research antibody division, MorphoSys AG is buying privately held Serotec Ltd. in a cash and stock deal valued at €29.3 million (US$35.3 million). (BioWorld Today)

Expecting to triple the revenues from its research antibody division, MorphoSys AG is buying privately held Serotec Ltd. in a cash and stock deal valued at €29.3 million (US$35.3 million). (BioWorld Today)

Lower-than-expected sales from its flagship cancer drug, Avastin, eclipsed solid fourth-quarter and full-year earnings for Genentech Inc., and caused the company's shares to fall nearly 5 percent in early trading Wednesday. (BioWorld Today)

Lower-than-expected sales from its flagship cancer drug, Avastin, eclipsed solid fourth-quarter and full-year earnings for Genentech Inc., and caused the company's shares to fall nearly 5 percent in early trading Wednesday. (BioWorld Today)

KAI Pharmaceuticals Inc. signed a potential $340 million deal expected to be announced today with Daiichi Sankyo Co. Ltd. for the global development and commercialization of KAI-9803. (BioWorld Today)